We are live on !
Find out more
Freestone Grove Partners Portfolio holdings
AUM
$15.6B
Turnover
60.27%
1-Year Est. Return
27.39%
This Fund
S&P 500
This Quarter Est. Return
+14.49%
1 Year Est. Return
+27.39%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$15.6B
AUM Growth
+$1.42B
(+10%)
Cap. Flow
+$81.1M
Cap. Flow % of AUM
Cap. Flow %
0.52%
Top 10 Holdings %
Top 10 Hldgs %
22.3%
Holding
1,397
New
435
Increased
253
Reduced
266
Closed
407
Avg Time Held
Equity + Options
0.3
years
Top 10 Avg Time Held
Equity + Options
0.2
years
Top 20 Avg Time Held
Equity + Options
0.1
years
Avg Time Held Equity only
0.3
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$311M |
| 2 |
Abbott
ABT
|
+$125M |
| 3 |
Vanguard S&P 500 ETF
VOO
|
+$121M |
| 4 |
SpaceX
SPCX
|
+$116M |
| 5 |
Procter & Gamble
PG
|
+$111M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Datadog
DDOG
|
+$128M |
| 2 |
Pinnacle Financial Partners Inc
PNFP
|
+$111M |
| 3 |
Elastic
ESTC
|
+$110M |
| 4 |
Twilio
TWLO
|
+$110M |
| 5 |
Intuitive Surgical
ISRG
|
+$109M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 19.5% |
| 2 | Financials | 16.81% |
| 3 | Miscellaneous | 15.64% |
| 4 | Technology | 13.57% |
| 5 | Healthcare | 10.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
776
Strategy Inc
MSTR
$65B
| $267K | ﹤0.01% |
+3,069
| New | +$445K |
2026 Q2
0 quarters
|
|
777
St. Joe Company
JOE
$3.9B
| $266K | ﹤0.01% |
+4,253
| New | +$279K |
2026 Q2
0 quarters
|
|
778
Royalty Pharma
RPRX
$27.7B
| $262K | ﹤0.01% |
4,670
-611,707
| -99% | -$31.8M |
2026 Q1
1 quarter
|
|
779
CorMedix
CRMD
$607M
| $262K | ﹤0.01% |
33,335
+23,003
| +223% | +$182K |
2026 Q1
1 quarter
|
|
780
Boise Cascade
BCC
$2.64B
| $257K | ﹤0.01% |
3,310
-319
| -9% | -$23.6K |
2026 Q1
1 quarter
|
|
781
Innovative Industrial Properties
IIPR
$1.45B
| $252K | ﹤0.01% |
4,067
+3,419
| +528% | +$192K |
2025 Q2
4 quarters
|
|
782
Federal Signal
FSS
$7.12B
| $248K | ﹤0.01% |
1,929
+1,552
| +412% | +$178K |
2025 Q4
2 quarters
|
|
783
Novavax
NVAX
$1.82B
| $247K | ﹤0.01% |
26,223
-1,953
| -7% | -$17.5K |
2025 Q4
2 quarters
|
|
784
Travere Therapeutics
TVTX
$4.96B
| $244K | ﹤0.01% |
4,294
+570
| +15% | +$25.3K |
2026 Q1
1 quarter
|
|
785
Transmedics
TMDX
$2.51B
| $235K | ﹤0.01% |
+3,537
| New | +$299K |
2026 Q2
0 quarters
|
|
786
Axcelis
ACLS
$3.6B
| $233K | ﹤0.01% |
1,228
-5,789
| -82% | -$859K |
2025 Q4
2 quarters
|
|
787
NBT Bancorp
NBTB
$2.67B
| $215K | ﹤0.01% |
+4,357
| New | +$199K |
2026 Q2
0 quarters
|
|
788
Satellogic
SATL
$606M
| $214K | ﹤0.01% |
+37,398
| New | +$274K |
2026 Q2
0 quarters
|
|
789
Boot Barn
BOOT
$3.52B
| $211K | ﹤0.01% |
1,286
-121,045
| -99% | -$19.6M |
2026 Q1
1 quarter
|
|
790
Blackstone Mortgage Trust
BXMT
$1.72B
| $210K | ﹤0.01% |
+12,388
| New | +$231K |
2026 Q2
0 quarters
|
|
791
Utz Brands
UTZ
$1.27B
| $207K | ﹤0.01% |
26,900
-73,698
| -73% | -$550K |
2026 Q1
1 quarter
|
|
792
C.H. Robinson
CHRW
$16.4B
| $203K | ﹤0.01% |
1,080
+1,067
| +8,208% | +$190K |
2025 Q1
5 quarters
|
|
793
Hewlett Packard
HPE
$77.2B
| $199K | ﹤0.01% |
4,420
-709,162
| -99% | -$25.6M |
2024 Q4
6 quarters
|
|
794
Bilibili
BILI
$5.6B
| $198K | ﹤0.01% |
+11,612
| New | +$235K |
2026 Q2
0 quarters
|
|
795
AdaptHealth
AHCO
$814M
| $196K | ﹤0.01% |
+18,844
| New | +$210K |
2026 Q2
0 quarters
|
|
796
Winmark
WINA
$1.01B
| $194K | ﹤0.01% |
459
+120
| +35% | +$46.9K |
2026 Q1
1 quarter
|
|
797
Dauch Corp
DCH
$1.15B
| $194K | ﹤0.01% |
+35,784
| New | +$217K |
2026 Q2
0 quarters
|
|
798
Aehr Test Systems
AEHR
$2.09B
| $189K | ﹤0.01% |
+1,970
| New | +$180K |
2026 Q2
0 quarters
|
|
799
Frontdoor
FTDR
$5.57B
| $188K | ﹤0.01% |
2,425
-3,055
| -56% | -$195K |
2026 Q1
1 quarter
|
|
800
BridgeBio Pharma
BBIO
$13.2B
| $188K | ﹤0.01% |
+2,524
| New | +$177K |
2026 Q2
0 quarters
|
|
Similar funds
Freestone Grove Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Freestone Grove Partners held 1,397 positions worth $15.6B, up 10% from $14.2B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Freestone Grove Partners's Q2 2026 filing shows 435 new, 253 increased, 266 reduced and 407 closed positions. Its largest new stake was Abbott: 1,372,846 shares worth $125M. The largest sale was Datadog, an estimated $128M.
By sector, the portfolio is most concentrated in Industrials at 20% of assets, up from 12% a quarter earlier, followed by Financials and Miscellaneous.
- Freestone Grove Partners's largest Q2 2026 buy was Abbott: 1,372,846 shares worth $125M.
- Freestone Grove Partners added most to iShares Core S&P 500 ETF in Q2 2026, an estimated $311M increase.
- Freestone Grove Partners's biggest Q2 2026 reduction was Elastic, cutting an estimated $110M.
- Freestone Grove Partners fully exited Datadog in Q2 2026, selling an estimated $128M.
- Freestone Grove Partners's ten largest holdings make up 22% of its $15.6B portfolio in Q2 2026.
- Freestone Grove Partners opened 435 new positions and closed 407 in Q2 2026.
- Freestone Grove Partners's portfolio value rose 10% quarter-over-quarter to $15.6B.
Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.